Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.6748
+0.0127 (1.92%)
At close: Aug 13, 2025, 4:00 PM
0.6433
-0.0315 (-4.67%)
Pre-market: Aug 14, 2025, 9:16 AM EDT

Moleculin Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
8.98.7910.0211.548.396.79
Upgrade
Research & Development
16.4217.7319.4918.9714.4212.76
Upgrade
Operating Expenses
25.4426.6429.6330.6422.9719.74
Upgrade
Operating Income
-25.44-26.64-29.63-30.64-22.97-19.74
Upgrade
Interest & Investment Income
0.210.551.370.240.310.01
Upgrade
Other Non Operating Income (Expenses)
-1.314.33-1.511.386.772.37
Upgrade
EBT Excluding Unusual Items
-26.55-21.76-29.77-29.03-15.89-17.36
Upgrade
Pretax Income
-26.55-21.76-29.77-29.03-15.89-17.36
Upgrade
Net Income
-26.55-21.76-29.77-29.03-15.89-17.36
Upgrade
Net Income to Common
-26.55-21.76-29.77-29.03-15.89-17.36
Upgrade
Shares Outstanding (Basic)
832221
Upgrade
Shares Outstanding (Diluted)
832221
Upgrade
Shares Change (YoY)
273.43%74.28%3.60%6.43%172.97%45.07%
Upgrade
EPS (Basic)
-3.15-6.32-15.07-15.22-8.87-26.44
Upgrade
EPS (Diluted)
-3.15-6.32-15.07-15.22-8.87-26.44
Upgrade
Free Cash Flow
-21.34-23.88-23.72-27.71-18.97-18.15
Upgrade
Free Cash Flow Per Share
-2.54-6.93-12.00-14.53-10.59-27.65
Upgrade
EBITDA
-25.32-26.52-29.5-30.51-22.8-19.54
Upgrade
D&A For EBITDA
0.120.130.130.130.160.2
Upgrade
EBIT
-25.44-26.64-29.63-30.64-22.97-19.74
Upgrade
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q